Using a quality improvement approach to improve care for latent tuberculosis infection

References

• WHO. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.
   Google Scholar
• Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152.
   PubMed Web of Science ®Google Scholar
• WHO. Global tuberculosis report 2015. Geneva: World Health Organization; 2015.
   Google Scholar
• WHO. Guidelines on the management of latent tuberculosis infection. WHO library cataloguing-in-publication data. Geneva: World Health Organization; 2015.
   Google Scholar
• Alsdurf H, Hill PC, Matteelli A, et al. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11): 1269–1278. •• Systematic review and meta-analysis of the cascade of care in latent TB..
   PubMed Web of Science ®Google Scholar
• Franco LM, Marquez L. Effectiveness of collaborative improvement: evidence from 27 applications in 12 less-developed and middle-income countries. BMJ Qual Saf. 2011;20(8): 658–665. • Systematic review of USAID funded quality improvement collaboratives..
   PubMed Web of Science ®Google Scholar
• Wells S, Tamir O, Gray J, et al. Are quality improvement collaboratives effective? A systematic review. BMJ Qual Saf. 2018;27(3):226–240.
   Google Scholar
• Institute of Medicine (US) Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century. Washington (DC): National Academies Press (US); 2001. 1990; 39–40.
   Google Scholar
• GL MR L, Nolan KM, Nolan TW, et al. The improvement guide: a practical approach to enhancing organizational performance. 2nd ed. San Francisco: Jossey-Bass Publishers; 2009.
   Google Scholar
• Varkey P, Reller MK, Resar RK. Basics of quality improvement in health care. Mayo Clin Proc. 2007;82(6):735–739.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services-Health Resources and Services Administration. Quality improvement. 2011. cited 2018 Mar 2. Available from: https://www.hrsa.gov/sites/default/files/quality/toolbox/508pdfs/qualityimprovement.pdf
   Google Scholar
• Taylor MJ, McNicholas C, Nicolay C, et al. Systematic review of the application of the plan-do-study-act method to improve quality in healthcare. BMJ Qual Saf. 2014;23(4):290–298.
   PubMed Web of Science ®Google Scholar
• Institute for Healthcare Improvement. The breakthrough series: IHI’s collaborative model for achieving breakthrough improvement. Boston: Institute for Healthcare Improvment; 2003.
   Google Scholar
• Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355(26):2725–2732.
   PubMed Web of Science ®Google Scholar
• Twum-Danso NA, Akanlu GB, Osafo E, et al. A nationwide quality improvement project to accelerate Ghana’s progress toward millennium development goal four: design and implementation progress. Int J Qual Health Care. 2012;24(6):601–611.
   PubMed Web of Science ®Google Scholar
• Sodzi-Tettey S, Twum-Danso NAY, Mobisson-Etuk N, et al. Lessons Learned from Ghana’s Project Fives Alive! A Practical Guide for Designing and Executing Large-Scale Improvement Initiatives. Cambridge, Massachusetts: Institute for Healthcare Improvement; 2015.
   Google Scholar
• Singh K, Brodish P, Speizer I, et al. Can a quality improvement project impact maternal and child health outcomes at scale in northern Ghana? Health Res Policy Syst. 2016;14(1):45.
   PubMedGoogle Scholar
• The Union. Operational research to improve health services. A guide for proposal development-2013. Int J Tubercul Lung Dis. 2013; ISBN 978-0-620-57795-3. [cited 2018 Sep 17]. Available from: https://www.theunion.org/what-we-do/publications/technical/english/2013-Operational-Research-to-Improve-Health-Services.pdf
   Google Scholar
• Standford University- Research compliance office. Quality assessment and quality improvement (QA/QI) FAQs. [cited 2018 Sep 18] Available from: https://humansubjects.stanford.edu/research/documents/qa_qi_faqs_AID03H16.pdf
   Google Scholar
• Silva AP, Hill P, Belo MT, et al. Non-completion of latent tuberculous infection treatment among children in Rio de Janeiro State, Brazil. Int J Tuberc Lung Dis. 2016;20(4):479–486.
   PubMed Web of Science ®Google Scholar
• LaCourse SM, Deya RW, Graham SM, et al. Evaluation of the isoniazid preventive therapy care cascade among HIV-positive female sex workers in Mombasa, Kenya. J Acquir Immune Defic Syndr. 2017;76(1):74–81.
   PubMed Web of Science ®Google Scholar
• Hirsch-Moverman Y, Daftary A, Franks J, et al. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis. 2008;12(11):1235–1254.
   PubMed Web of Science ®Google Scholar
• Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, et al. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis. 2016;16:257.
   PubMed Web of Science ®Google Scholar
• Szkwarko D, Hirsch-Moverman Y, Du Plessis L, et al. Child contact management in high tuberculosis burden countries: a mixed-methods systematic review. PLoS One. 2017;12(8):e0182185.
   PubMed Web of Science ®Google Scholar
• De Perio MA, Niemeier RT, Groenewold MR. The effectiveness of using interferon-gamma release assays in screening immigration employees for latent tuberculosis infection. Int J Occup Environ Health. 2011;17(4):322–327.
   PubMed Web of Science ®Google Scholar
• Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162(6):2033–2038.
   PubMed Web of Science ®Google Scholar
• Goswami ND, Hecker E, Holland DP, et al. Feasibility and willingness-to-pay for integrated community-based tuberculosis testing. BMC Infect Dis. 2011;11:305.
   PubMed Web of Science ®Google Scholar
• Sahni R, Miranda C, Yen-Lieberman B, et al. Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers? Infect Control Hosp Epidemiol. 2009;30(2):197–199.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Coe A, Bliss C, et al. Acceptance of interferon-gamma release assay by a high-risk urban cohort. Int J Tuberc Lung Dis. 2011;15(10):1334–1339.
   PubMed Web of Science ®Google Scholar
• Pai M, Behr M. 2016. Latent Mycobacterium tuberculosisinfection and interferon-gamma release assays. Microbiol Spectrum4(5):TBTB2-0023-2016. doi:10.1128/microbiolspec.TBTB2-0023 -2016.
   Google Scholar
• Aggerbeck H, Giemza R, Joshi P, et al. Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS One. 2013;8(5):e64215.
   PubMed Web of Science ®Google Scholar
• Hoff ST, Peter JG, Theron G, et al. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J. 2016;47(3):919–928.
   PubMed Web of Science ®Google Scholar
• Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146(5):340–354.
   PubMed Web of Science ®Google Scholar
• Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011;204(Suppl 4):S1120–S1129.
   PubMedGoogle Scholar
• Sester M, Sotgiu G, Lange C, et al. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):100–111.
   PubMed Web of Science ®Google Scholar
• Kahwati LC, Feltner C, Halpern M, et al. Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016;316(9):970–983.
   PubMed Web of Science ®Google Scholar
• WHO Tuberculosis Research Office. Further studies of geographic variation in naturally acquired tuberculin sensitivity. Bulletin of the World Health Organization. 1955;12(1-2):63–83.
   Google Scholar
• Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent mycobacterium tuberculosis infection. JAMA. 2001;286(14):1740–1747.
   PubMed Web of Science ®Google Scholar
• Cattamanchi A, Smith R, Steingart KR, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2011;56(3):230–238.
   PubMed Web of Science ®Google Scholar
• Huo ZY, Peng L. Accuracy of the interferon-gamma release assay for the diagnosis of active tuberculosis among HIV-seropositive individuals: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:350.
   PubMed Web of Science ®Google Scholar
• Menzies D, Tannenbaum TN, FitzGerald JM. Tuberculosis: 10. Prevention. CMAJ. 1999;161(6):717–724.
   PubMed Web of Science ®Google Scholar
• Froeschle JE, Ruben FL, Bloh AM. Immediate hypersensitivity reactions after use of tuberculin skin testing. Clin Infect Dis. 2002;34(1):E12–E13.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Sturdy P, Brewin P, et al. Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial. Lancet. 2007;369(9572):1528–1534.
   PubMed Web of Science ®Google Scholar
• Durovni B, Saraceni V, Moulton LH, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis. 2013;13(10):852–858.
   PubMed Web of Science ®Google Scholar
• Uwimana J, Zarowsky C, Hausler H, et al. Training community care workers to provide comprehensive TB/HIV/PMTCT integrated care in KwaZulu-Natal: lessons learnt. Trop Med Int Health. 2012;17(4):488–496.
   PubMed Web of Science ®Google Scholar
• Duarte R, Neto M, Carvalho A, et al. Improving tuberculosis contact tracing: the role of evaluations in the home and workplace. Int J Tuberc Lung Dis. 2012;16(1):55–59.
   PubMed Web of Science ®Google Scholar
• Rocha C, Montoya R, Zevallos K, et al. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational assessment. Int J Tuberc Lung Dis. 2011;15(Suppl 2):50–57.
   PubMedGoogle Scholar
• Steele AW, Eisert S, Davidson A, et al. Using computerized clinical decision support for latent tuberculosis infection screening. Am J Prev Med. 2005;28(3):281–284.
   PubMed Web of Science ®Google Scholar
• Alvarez GG, VanDyk DD, Aaron SD, et al. Taima (stop) TB: the impact of a multifaceted TB awareness and door-to-door campaign in residential areas of high risk for TB in Iqaluit, Nunavut. PLoS One. 2014;9(7):e100975.
   PubMed Web of Science ®Google Scholar
• Lutge EE, Wiysonge CS, Knight SE, et al. Incentives and enablers to improve adherence in tuberculosis. Cochrane Database Syst Rev. 2015;9:CD007952.
   Google Scholar
• Liu Q, Abba K, Alejandria MM, et al. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database Syst Rev. 2014;11:CD006594.
   Google Scholar
• Pilote L, Tulsky JP, Zolopa AR, et al. Tuberculosis prophylaxis in the homeless. A trial to improve adherence to referral. Arch Intern Med. 1996;156(2):161–165.
   PubMedGoogle Scholar
• Brugueras S, Orcau A, Millet JP, et al. Tuberculosis clinical units improve contact tracing. Int J Tuberc Lung Dis. 2016;20(12):1572–1579.
   PubMed Web of Science ®Google Scholar
• Green EP, Catalani C, Keny A, et al. Do clinical decision-support reminders for medical providers improve isoniazid prescription rates among HIV-positive adults? Washington, DC: USAID | Project Search: HIVCore; 2015. ( HIVCore Final Report).
   Google Scholar
• Goldberg SV, Wallace J, Jackson JC, et al. Cultural case management of latent tuberculosis infection. Int J Tuberc Lung Dis. 2004;8(1):76–82.
   PubMed Web of Science ®Google Scholar
• Zachariah R, Spielmann MP, Harries AD, et al. Passive versus active tuberculosis case finding and isoniazid preventive therapy among household contacts in a rural district of Malawi. Int J Tuberc Lung Dis. 2003;7(11):1033–1039.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Sharma A, Kadhiravan T, et al. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev. 2013;CD007545.
   PubMed Web of Science ®Google Scholar
• Zenner D, Beer N, Harris RJ, et al. Treatment of latent tuberculosis infection: an updated network meta-analysis. Ann Intern Med. 2017;167(4):248–255.
   PubMed Web of Science ®Google Scholar
• Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847–850.
   PubMed Web of Science ®Google Scholar
• Menzies D, Adjobimey M, Ruslami R, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–453.
   PubMed Web of Science ®Google Scholar
• Diallo T, Adjobimey M, Ruslami R, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379(5):454–463.
   PubMed Web of Science ®Google Scholar
• Holland DP, Sanders GD, Hamilton CD, et al. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179(11):1055–1060.
   PubMed Web of Science ®Google Scholar
• Shepardson D, Marks SM, Chesson H, et al. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17(12):1531–1537.
   PubMed Web of Science ®Google Scholar
• Campbell JR, Johnston JC, Sadatsafavi M, et al. Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PLoS One. 2017;12(10):e0186778.
   PubMed Web of Science ®Google Scholar
• Esfahani K, Aspler A, Menzies D, et al. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials. Int J Tuberc Lung Dis. 2011;15(10):1340–1346.
   PubMed Web of Science ®Google Scholar
• Menzies D, Dion MJ, Rabinovitch B, et al. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med. 2004;170(4):445–449.
   PubMed Web of Science ®Google Scholar
• Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689–697.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–2166.
   PubMed Web of Science ®Google Scholar
• Chan PC, Yang CH, Chang LY, et al. Latent tuberculosis infection treatment for prison inmates: a randomised controlled trial. Int J Tuberc Lung Dis. 2012;16(5):633–638.
   PubMed Web of Science ®Google Scholar
• Sterling TR, Moro RN, Borisov AS, et al. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. Clin Infect Dis. 2015;61(4):527–535.
   PubMed Web of Science ®Google Scholar
• DeLuca A, Frick M, Lessem E, et al. Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations. Public Health Action. 2014;4(4):238–242.
   PubMedGoogle Scholar
• Belknap R, Holland D, Feng PJ, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167(10):689–697.
   PubMed Web of Science ®Google Scholar
• M’Imunya JM, Kredo T, Volmink J. Patient education and counselling for promoting adherence to treatment for tuberculosis. Cochrane Database Syst Rev. 2012;5:CD006591.
   PubMedGoogle Scholar
• Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015;5:CD003343.
   Google Scholar
• Fos PJ, Lee JE, Sung JH, et al. The role of quality improvement in disease management: a statewide tuberculosis control success story. J Public Health Manag Pract. 2005;11(3):222–227.
   PubMed Web of Science ®Google Scholar